Elevara Medicines is a clinical-stage biotech. ELV001 targets fibroblast-like synoviocytes and synergizes with DMARDs to achieve clinical remission in RA.
Location: United Kingdom
Total raised: $70M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 23.10.2025 | Series A | $70M | Sofinnova ... |
Mentions in press and media 2
| Date | Title | Description |
| 23.10.2025 | Elevara Medicines Raises $70M in Series A Funding | Elevara Medicines, a London, UK-based clinical-stage biotech developing therapies for rheumatoid arthritis (RA) and chronic inflammatory diseases, closed a $70m Series A financing. The round was co-led by Forbion and Sofinnova Partners, wit... |
| - | Elevara Medicine | “Elevara Medicines is a clinical-stage biotech. ELV001 targets fibroblast-like synoviocytes and synergizes with DMARDs to achieve clinical remission in RA.” |